All In Biotech

Drug Trial Radar · NCT04729751

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome

Last checked: Nov 20, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

27

Actual

Start

Sep 9, 2021

Primary completion

Dec 17, 2024

Study completion Dec 17, 2024

Sponsor

Lead sponsor
Mirum Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jan 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 days, up to 364 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess whether the investigational drug maralixibat, is safe and well tolerated in children \<12 months of age with Alagille Syndrome \[ALGS\] or Progressive Familial Intrahepatic Cholestasis \[PFIC\].

Conditions

  • Progressive Familial Intrahepatic Cholestasis
  • Alagille Syndrome
  • Cholestatic Liver Disease

Interventions

  • MaralixibatDrug

    Maralixibat chloride provided in the form of an oral solution (i.e., 5, 10, 15, and 20 mg/mL) * 400 μg/kg maralixibat chloride is equivalent to 380 µg/kg maralixibat free base * 600 μg/kg maralixibat chloride is equivalent to 570 µg/kg maralixibat free base

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Treatment-emergent Adverse Events [TEAEs]Time frame: From Baseline through to Week 13

Locations

14 sites in 7 countries. Site status is shown where the registry gives one.

  • Children Hospital LA

    Los Angeles, California

  • University of California - San Francisco

    San Francisco, California

  • Medstar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Ochsner Hospital for Children

    New Orleans, Louisiana

  • Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • Texas Children's Hospital

    Houston, Texas

  • Seattle Children's Hospital

    Seattle, Washington

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Sociedade Beneficente de Senhoras - Hospital Sírio-Libanês

    São Paulo, Brazil

  • Hôpital Kremlin Bicêtre

    Le Kremlin-Bicêtre, France

  • Hopital Necker

    Paris, France

  • Consultorio de Joshue David Covarrubias Esquer

    Zapopan, Mexico

  • Instytut Pomnik-Centrum Zdrowia Dziecka

    Warsaw, Poland

  • King's College Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.